Correspondence | Published:

Fragile X population carrier screening

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Dimmock DP. Should we implement population screening for fragile X? Genet Med 2017;19:1329–1333.

  2. 2

    Metcalfe SA, Martyn M, Ames A et al. Informed decision making and psychosocial outcomes in pregnant and nonpregnant women offered population fragile X carrier screening. Genet Med 2017;19:1380–1389.

  3. 3

    Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317–319.

  4. 4

    Archibald AD, Hickerton CL, Wake SA, Jaques AM, Cohen J, Metcalfe SA. “It gives them more options”: preferences for preconception genetic carrier screening for fragile X syndrome in primary healthcare. J Community Genet 2016;7:159–171.

Download references

Author information

Conflict of Interest

M.D. and A.A. are employees of the Victorian Clinical Genetics Services, which provides a fee-for-service carrier screening panel (Prepair) for cystic fibrosis, spinal muscular atrophy, and fragile X syndrome. It is a not-for-profit specialist laboratory and clinical genetics service, and a wholly owned subsidiary of the Murdoch Children’s Research Institute. The other authors declare no conflict of interest.

Correspondence to Sylvia A Metcalfe BSc, PhD.

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article